Trial Profile
A Large, International, Randomized, Placebo-controlled Trial to Assess the Impact of Dabigatran (a Direct Thrombin Inhibitor) and Omeprazole (a Proton-pump Inhibitor) in Patients Suffering Myocardial Injury After Noncardiac Surgery
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 28 Dec 2021
Price :
$35
*
At a glance
- Drugs Dabigatran etexilate (Primary) ; Omeprazole (Primary)
- Indications Cardiovascular disorders; Embolism and thrombosis; Gastrointestinal haemorrhage; Myocardial disorders
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms MANAGE
- 26 Jul 2021 Primary endpoint (Major vascular complication (for Dabigatran)) has been met, results published in the American Journal of Cardiovascular Drugs.
- 26 Jul 2021 Results assessing the cost implications of the MANAGE trial from a Canadian perspective, published in the American Journal of Cardiovascular Drugs
- 02 Feb 2019 This trial has been completed in United Kingdom, according to the European Clinical Trials Database record.